- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.04. | Why ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday? | 2 | Insider Monkey | ||
| 08.04. | ZyVersa CEO outlines progress in kidney disease drug development | 4 | Investing.com | ||
| 08.04. | ZyVersa-CEO erläutert Fortschritte bei der Entwicklung von Medikamenten gegen Nierenerkrankungen | 4 | Investing.com Deutsch | ||
| 08.04. | ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS) | 107 | GlobeNewswire (Europe) | WESTON, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; "ZyVersa"), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment... ► Artikel lesen | |
| 07.04. | ZyVersa Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.04. | ZyVersa Therapeutics files to sell 4.21M shares of common stock by selling shareholders | 1 | Seeking Alpha | ||
| ZYVERSA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 27.03. | ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update | 134 | GlobeNewswire (Europe) | KEY HIGHLIGHTS: Phase 2a proof-of concept clinical trial for Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease (DKD) expected to begin H1-2025. Regulatory path for VAR... ► Artikel lesen | |
| 27.03. | ZyVersa Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 18.03. | ZyVersa's IC 100 shows promise in OAC treatment study | 1 | Investing.com | ||
| 18.03. | ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study | 1 | GlobeNewswire (USA) | ||
| 12.03. | ZyVersa: Preclinical Data Supports Potential Of IC 100 Against Alzheimer's, Parkinsons | - | RTTNews | ||
| 12.03. | ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer's Disease Mouse Model | 3 | GlobeNewswire (USA) | ||
| 07.03. | ZyVersa Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 06.03. | ZyVersa Therapeutics announces pricing of $2M private placement | 2 | Seeking Alpha | ||
| 06.03. | ZyVersa sichert sich 2 Millionen US-Dollar für Medikamentenentwicklung | 1 | Investing.com Deutsch | ||
| 06.03. | ZyVersa secures $2 million in funding for drug development | 1 | Investing.com | ||
| 05.03. | ZyVersa's IC 100 shows promise in heart failure treatment | 1 | Investing.com | ||
| 05.03. | ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure ... | 99 | GlobeNewswire (Europe) | Heart failure with preserved ejection fraction (HFpEF), a chronic inflammatory condition, is a leading cause of morbidity and mortality globally. Obesity, diabetes, and hypertension are highly prevalent... ► Artikel lesen | |
| 24.01. | ZyVersa Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 20.11.24 | ZyVersa reports progress on stroke-related heart injury treatment | 2 | Investing.com |
Seite:
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 40,860 | 0,00 % | Illumina, Tempus AI To Collaborate To Accelerate Genomic AI Innovation | SAN DIEGO (dpa-AFX) - Illumina Inc. (ILMN) and Tempus AI, Inc. (TEM), Tuesday announced a collaboration to accelerate clinical adoption of next-generation sequencing tests through novel evidence... ► Artikel lesen | |
| ARCELLX | 60,69 | 0,00 % | Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights | REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,320 | 0,00 % | Recursion lizenziert HealthVerity-Echtweltdaten für klinische Studien | ||
| AVIDITY BIOSCIENCES | 25,760 | 0,00 % | Avidity Biosciences Inc Aktie: Routinebericht des Unternehmens | Avidity Biosciences hat die Rekrutierung für die Biomarker-Kohorte der Phase-1/2-FORTITUDE-Studie für Delpacibart Braxlosiran (Del-Brax) abgeschlossen. Diese Studie zielt auf Patienten mit fazioskapulohumeraler... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 32,040 | 0,00 % | Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results | Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A 16-week data expected mid-2025 APG279 (APG777 + APG990)... ► Artikel lesen | |
| EVOTEC | 6,210 | +6,70 % | Evotec: Am Donnerstag zählt es! | Vor dem Osterwochenende sollten Anleger die Aktie des Hamburger Wirkstoffforschers Evotec mit Argusaugen verfolgen. Denn am Gründonnerstag (17. April) will das Unternehmen die Ergebnisse für das vergangene... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 13,030 | 0,00 % | Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) |
- Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM -- Four-week treatment with EDG-7500 demonstrated... ► Artikel lesen | |
| QIAGEN | 35,620 | -2,89 % | MIDDAY BRIEFING - Unternehmen und Märkte: BEIERSDORF, CARL ZEISS MEDITEC, PATRIZIA, QIAGEN, PROSIEBENSAT1, BOEING, ERICSSON, JOHNSON & JOHNSON, TOTALENERGIES | DJ MIDDAY BRIEFING - Unternehmen und Märkte
Der Markt-Überblick am Mittag, zusammengestellt von Dow Jones Newswires:
+++++ FEIERTAGSHINWEIS +++++
MITTWOCH: An der Börse in Oslo... ► Artikel lesen | |
| DYNE THERAPEUTICS | 7,830 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments | - Vikram Ranade, PhD, appointed as chief business officer - - Ranjan Batra, PhD, appointed as chief scientific officer - - Oxana Beskrovnaya, PhD, transitioning to chief innovation officer - WALTHAM... ► Artikel lesen | |
| 89BIO | 5,890 | 0,00 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,230 | 0,00 % | Why ADMA Biologics, Inc. (ADMA) Skyrocketed On Tuesday? | ||
| TREVI THERAPEUTICS | 6,100 | 0,00 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates | Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 23,050 | 0,00 % | Here's Why Summit Therapeutics Stock Soared 15% on Friday | ||
| MINERALYS THERAPEUTICS | 13,500 | 0,00 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's ... | - Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 18,530 | 0,00 % | JMP maintains $87 target on Structure Therapeutics shares |
ZYVERSA THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,710 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ZYVERSA THERAPEUTICS INC finden Sie auf Wallstreet Online.
